Current Progress on the Genomics of Schistosomiasis for Drug Discovery and Diagnostics

Author(s): Nileshkumar Meghani, Beom-Jin Lee, Hardik Amin, Behzad Nili-Ahmadabadi, Saraswathy Nagendran*

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders

Volume 20 , Issue 5 , 2020

Become EABM
Become Reviewer
Call for Editor


For a number of decades, schistosomiasis has remained a public threat and an economic burden in a number of countries, directly impacting over 200 million people. The past 15 years have seen tremendous progress in the development of high-throughput methods for targeting or compound selection that are vital to early-stage schistosome drug discovery research. Genomewide approaches to analyze gene expression at the transcriptional and other -omic levels have helped immensely for gaining insight into the pathways and mechanisms involved in the schistosomiasis and it is expected to revolutionize the drug discovery as well as related diagnostics. This review discusses the most recent progress of pharmacology and genomics concerning schistosomiasis with a focus on drug discovery and diagnostic tools. It also provides chemical structural insights of promising targets along with available in vitro and/or in vivo data. Although significant research has been done to identify new molecules for the treatment and new methods for diagnosis, the necessity of new options for the sustainable control of schistosomiasis remains a great challenge.

Keywords: Genomics, drug discovery, personalized medicine, schistosomiasis vaccine, praziquantel, pharmacology.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2020
Published on: 09 December, 2020
Page: [598 - 610]
Pages: 13
DOI: 10.2174/1871526519666191015170536
Price: $65

Article Metrics

PDF: 17